Contact

Peptide Resources for Immunotherapy & Cell Therapy

About Immunotherapy & Cell Therapy

 Cellular therapy (also called cell therapy or cytotherapy) & immunotherapy aim to treat or prevent disease by injecting living cells or (peptide) vaccines into the patient (e.g. cancer immunotherapy). There are multiple strategies for cell therapy that differ by the cell type or the method used. Examples include types of cell therapy like allogeneic cell therapy, embryonic stem cell therapy, or immunotherapy. Immunological cytotherapy approaches like adoptive T cell therapy (including CAR), and dendritic cell therapy as a vaccination strategy use peptides to produce different types of antigen-specific immune cells e.g. for cancer immunotherapy

Benefits of Using Peptides as Antigens for Immunotherapy

  • Neo-epitopes enable personalized therapies
  • Peptides ensure robust epitope resolved immune monitoring
  • Only peptides allow the study of B- and T-cell epitope spreading
  • Peptides can be synthesized in high purities
  • Peptides allow proteome-wide target identification
  • No antigen expression needed, ADCF policy applicable
  • Sequence diversity and post-translational modifications can be addressed

Why Work with JPT?

  • We are the quality leader for peptides in immunotherapy
  • We develop unique technologies for discovery, therapy and immune monitoring
  • We understand your application
  • We have a long track record of successful projects and collaborations
  • Over 1000 peer reviewed papers with our products
  • We are ISO 9001:2015 certified

JPT's Peptide Resources for Immunotherapy & Cell Therapy:

Disclaimer:
JPT GxP peptides are not intended for human in vivo application.  JPT does not warrant that any peptides and peptide pools produced under GxP conditions are applicable in clinical applications (clinical grade peptides). JPT invites its customers to visit, inspect and audit our facilities to make an educated decision on whether or not peptides or peptide pools produced under GxP conditions are suited for a specific application.

Selected References for Immunotherapy


"Personalized RNA Mutanome Vaccines Mobilize Poly-specific Therapeutic Immunity Against Cancer"
Sahin et al., Nature (2017) - PMID: 28678784
"An Immunogenic Personal Neoantigen Vaccine for Patients with Melanoma"
Ott et al., Nature (2017) - PMID: 28678778
"Low Dose Gemcitabine-loaded Lipid Nanocapsules Target Monocytic Myeloid-derived Suppressor Cells and Potentiate Cancer Immunotherapy"
Sasso et al., Biomaterials (2016)
"Specific Cytotoxic T-cell Immune Responses Against Autoantigens Recognized by Chronic Lymphocytic Leukaemia Cells"
Zaleska et al., Br J Haematol. (2016) - PMID: 27097566
"Epstein-Barr Virus Reactivation Does Not Impact Total T-Cell Reconstitution But Is Associated With Decreased Functional T Cells after Stem Cell Transplantation"
Pietersma et al., J Clin Cell Immunol (2015)
"Selection of Adenovirus-specific and Epstein-Barr virus–specific T Cells With Major Histocompatibility Class I Streptamers Under Good Manufacturing Practice (GMP)–Compliant Conditions"
Freimüller et al., Cytotherapy (2015) – PMID: 25866178
"A Single Exercise Bout Enhances the Manufacture of  Viral-Specific T-cells from Healthy Donors: Implications for Allogeneic Adoptive Transfer Immunotherapy"
Spielmann et al., Sci Rep (2016) - PMID: 27181409
"Broadly-specific Cytotoxic T Cells Targeting Multiple HIV Antigens Are Expanded From HIV+ Patients: Implications for Immunotherapy"
Lam et al., Molecular Therapy (2015) - PMID: 25366030
"Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir"
Sung et al., Journal of Infectious Diseases (2015) - PMID: 25589335
"Ex vivo Expansion of Human T cells for Adoptive Immunotherapy Using the Novel Xeno-free CTS Immune Cell Serum Replacement"
Smith et al., Clinical & Translational Immunology (2015) - PMID: 25671129
"A Phase I Trial Combining Decitabine/dendritic Cell Vaccine Targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for Children with Relapsed or Therapy-Refractory Neuroblastoma and Sarcoma"
Krishnadas et al., Cancer Immunol Immunother. (2015) - PMID: 26105625
"The Tuberculosis Vaccine H4: IC31 is Safe and Induces a Persistent Polyfunctional CD4 T cell Response in South African Adults: A Randomized Controlled Trial"
Geldenhuys et al., Vaccine (2015) - PMID: 26048780
"Identification of Novel Antiacetylated Vimentin Antibodies in Patients with Early Inflammatory Arthritis"
Juarez et al., Ann Rheum Dis (2015)

> More references

 

 

Selected Testimonials for Immunotherapy


"My group is developing therapeutic strategies for using in vitro expanded virus-specific T cells (VSTs) for the treatment of viral infections in immunocompromised patients. We recently demonstrated the feasibility and clinical benefit associated with the infusion of rapidly generated single-culture VSTs, manufactured using JPT's GxP PepMix™ peptide pools covering 12 immunogenic antigens from five viruses (EBV, AdV, CMV, BK, and HHV6). When administered to 11 allogeneic stem cell transplant recipients, 8 of whom had up to four active infections, these VSTs produced an overall 94% response rate."

Ann Leen, PhD, Baylor College of Medicine, Houston, TX, USA.

"We utilize customized 15-mer PepMix™ peptide pools encoding for weak tumor associated antigens for immunomonitoring of cancer patients treated with recombinant therapeutic vaccines.  Our experience with JPT has been outstanding in regard to product quality and communication with scientific and administrative customer service.  JPT is the only company we trust to synthesize the 15-mer peptides and corresponding pools for our clinical trial evaluations."
Benedetto Farsaci, National Cancer Institute, NIH, Bethesda, MD, USA

"Our work focuses on TGF-beta in physiology and cancer as well as the differentiation and expansion of human T cells in vitro for  adoptive immunotherapy. For our early phase clinical trials we are in need of T cell EBV specific stimulants having an exceptional quality. JPT's customized  PepMix™ Peptide Pools not only proved to deliver excellent performance in our in vitro culture systems but accompanying QC/QA documentation was essential to prepare our application to our regulatory agency."
Dr. Jean-Sébastien Delisle, Université de Montréal, Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Canada

> More testimonials

Check our list of products,
click and go.

News Highlights

Quality Assurance

All production is performed according to ISO 9001:2015 standards

Stay in touch and be the first to receive the latest news!